Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates.

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

I am an 81-year-old man (5-foot-2 at 122 pounds) in good health, except that I have Type 2 diabetes. My A1C level has been in ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

Researchers have found in a observational study that dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for ...

"Among dialysis patients with osteoporosis, denosumab may be more effective than oral bisphosphonates in reducing fracture ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

Patients with osteoporosis who took bisphosphonates, especially risedronate, were at a higher risk of developing acute angle ...